Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size By Type (Wet AMD, Dry AMD), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at USD 10.4 billion in 2023 and is projected to reach USD 18.7 billion by 2031, growing at a CAGR of 7.5% during the forecast period of 2023–2031. The market growth is driven by the rising geriatric population, increasing prevalence of AMD, advancements in biologics and gene therapies, and growing awareness about early treatment. Age-related macular degeneration, particularly its neovascular (wet) form, has become a leading cause of vision loss in the elderly population, thereby generating strong demand for innovative and effective therapeutics.

Drivers:

1. Rising Prevalence of AMD:

The global incidence of AMD is growing, with millions affected annually, especially in aging populations. This trend is intensifying demand for effective therapeutic options.

2. Technological Advancements in Treatment:

Breakthroughs in biologics, anti-VEGF therapies, and gene therapies are transforming the AMD therapeutics landscape. Treatments like faricimab and port delivery systems are revolutionizing patient outcomes and convenience.

3. Growing Geriatric Population:

An aging demographic worldwide increases the patient pool for AMD, particularly in high-income countries. This demographic shift sustains the long-term growth of the market.

Restraints:

1. High Cost of Advanced Therapies:

Innovative treatments, particularly biologics, come with high price tags that may limit access in lower-income regions and place a burden on healthcare systems.

2. Limited Access in Developing Economies:

Many developing nations face challenges in adopting advanced therapeutics due to weak ophthalmic infrastructure and insufficient reimbursement policies.

Opportunity:

1. Emerging Gene and Cell-Based Therapies:

Cutting-edge innovations in gene and stem cell therapies are offering long-lasting or even curative treatment potential, creating substantial opportunities for new market entrants.

2. Market Penetration in Emerging Economies:

Increasing healthcare investment in countries like China, India, and Brazil presents untapped opportunities for AMD treatment expansion, supported by rising awareness and healthcare reforms.

Market by System Type Insights:

Based on therapy type, Anti-VEGF (Vascular Endothelial Growth Factor) therapies held the largest share in 2023. Products such as aflibercept and ranibizumab dominate the market due to their established efficacy in controlling wet AMD. However, emerging gene therapies are anticipated to witness the highest growth during the forecast period, driven by their long-acting effects and reduced treatment frequency.

Market by End-use Insights:

By end-use, hospitals and specialty ophthalmic clinics accounted for the largest market share in 2023. These facilities are preferred due to their access to specialized care, infrastructure for administering intravitreal injections, and established patient monitoring protocols. The homecare and teleophthalmology segment is expected to grow at a notable pace, propelled by digital health technologies and the demand for remote care solutions.

Market by Regional Insights:

In 2023, North America led the global AMD therapeutics market, supported by high healthcare spending, advanced diagnostic capabilities, and strong R&D investment. However, the Asia-Pacific region is forecasted to grow at the fastest rate, due to a large aging population base, increasing urbanization, and rising awareness of age-related eye diseases.

Competitive Scenario:

Key players in the AMD therapeutics market include Roche (Genentech), Regeneron Pharmaceuticals, Novartis AG, Bayer AG, Apellis Pharmaceuticals, Kodiak Sciences, and Iveric Bio (an Astellas company). These companies are engaged in pipeline innovation, strategic collaborations, and regional expansions. Notable recent developments include:

2023: Roche launched Vabysmo (faricimab) in new international markets, following successful clinical outcomes with dual-pathway inhibition.

2024: Apellis received expanded approval for pegcetacoplan in treating geographic atrophy, significantly expanding its addressable market.

2025: Iveric Bio, under Astellas, initiated late-stage trials for gene therapy-based solutions targeting dry AMD.

Scope of Work – Global Age-Related Macular Degeneration (AMD) Therapeutics Market

Key Market Developments:

Feb 2023: Genentech’s Vabysmo showed strong real-world outcomes in reducing treatment burden for wet AMD.

Nov 2024: Novartis announced clinical success for its long-acting ocular implant designed for sustained drug delivery.

May 2025: Regeneron’s aflibercept 8 mg received FDA approval for extended dosing in wet AMD.

FAQs:

What is the current market size of the Global Age-Related Macular Degeneration (AMD) Therapeutics Market?

The market was valued at USD 10.4 billion in 2023.

What is the major growth driver of the Global Age-Related Macular Degeneration (AMD) Therapeutics Market?

Increasing prevalence of AMD and advancements in therapeutic technologies are key drivers.

Which is the largest region during the forecast period in the Global Age-Related Macular Degeneration (AMD) Therapeutics Market?

North America remains the largest regional market.

Which segment accounted for the largest market share in Global Age-Related Macular Degeneration (AMD) Therapeutics Market?

The Anti-VEGF therapy segment dominated the market in 2023.

Who are the key market players in the Global Age-Related Macular Degeneration (AMD) Therapeutics Market?

Roche, Regeneron, Novartis, Bayer, Apellis Pharmaceuticals, and Iveric Bio are among the leading players.